Perspective Therapeutics, Inc.

CATX NYSE SEC CIK 728387
Follow Perspective Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$32.4M −24.9% vs same quarter last year
EPS, diluted −$0.27 +22.9% vs same quarter last year
Operating cash flow −$31.4M −92.4% vs same quarter last year
Operating income −$34.3M −23.2% vs same quarter last year
Net income by quarter
−$40.2M
−$18.2M
−$21.5M
−$26M
−$37.5M
−$26.2M
−$26.8M
−$32.4M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$150M−$100M−$50M$0$50MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25-−$103.1M
FY24-−$79.3M
FY23$1.4M−$46.5M
FY22$0−$7.3M
FY21$10.1M−$3.4M
FY20$9.7M−$3.4M
FY19$7.3M−$5.1M
FY18$5.9M−$6.7M
FY17$4.8M−$6.2M
FY16$4.8M−$4.7M
FY15$4.6M−$3.7M
FY14$4.2M−$6M
FY13$4.5M−$3.9M
FY12$5.1M−$3.5M
FY11$5.2M−$2.8M
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−4000%−3000%−2000%−1000%0%1000%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearGross marginOperating marginNet margin
FY25---
FY24---
FY23100%−2855%−3243.2%
FY22---
FY2150.9%−34.3%−33.7%
FY2052.9%−35.9%−35.6%
FY1941.7%−71.8%−70.3%
FY1831.1%−113.6%−113.1%
FY1717.6%−132.5%−129.4%
FY162.7%−106.6%−98.8%
FY153.6%−94.2%−79.9%
FY14−4.7%−108.7%−141.2%
FY133.3%−89.9%−85.2%
FY1213.9%−71%−68.8%
FY1122.1%−56.6%−54.3%
Free cash flowOperating cash flow minus capital expenditure
−$100M−$75M−$50M−$25M$0FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$95.2M
FY24−$72.7M
FY23−$38M
FY22−$8M
FY21−$3.2M
FY20−$3.9M
FY19−$5.5M
FY18−$6M
FY17−$6.3M
FY16−$4.4M
FY15−$3.7M
FY14−$3.2M
FY13−$3.1M
FY12−$2.5M
FY11−$2.6M
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Perspective Therapeutics
  • Healthcare median
−4000%−3000%−2000%−1000%0%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearPerspective TherapeuticsHealthcare median
FY25-−30.6%
FY24-−47%
FY23−3243.2%−58%
FY22-−80.4%
FY21−33.7%−71.9%
FY20−35.6%−62.2%
FY19−70.3%−46.3%
FY18−113.1%−49.6%
FY17−129.4%−45.9%
FY16−98.8%−36%
FY15−79.9%−38.4%
FY14−141.2%−35.5%
FY13−85.2%−37.1%
FY12−68.8%−29.1%
FY11−54.3%−27.9%